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Background Eczema control has been identified as an important outcome by key
stakeholders in eczema research (including patients, carers, healthcare profession-
als and researchers) but no validated instruments for the domain have been
identified.
Objectives To develop a measurement instrument to capture a patient’s perspective
of eczema control that is suitable for use in eczema clinical trials.
Methods Best practice for the development of a patient-reported outcome
was followed. A mixed-methods approach was used to develop and refine
a conceptual framework, generate, refine and select items and to test the
distribution and construct validity of the final scale. The mixed-methods
approach involved expert panel meetings (including patient representatives,
healthcare professionals and methodologists), and data collection using a
focus group, cognitive interviews and an online survey with people with
eczema and caregivers. Multivariable linear regression was used in the item
selection process.
Results Fourteen expert panel members co-produced the instrument, with input
from people with eczema and caregivers via a focus group (n = 6), cognitive
interviews (n = 13) and an online survey (n = 330). The resulting instrument,
Recap of atopic eczema (RECAP), is a seven-item questionnaire that captures
eczema control via self or caregiver report. The development process aimed to
ensure good content validity and feasibility. Initial testing suggested no floor or
ceiling effects and good construct validity. Hypothesized correlation with the
Patient-Oriented Eczema Measure was confirmed [r(258) = 083, P < 0001].
Conclusions RECAP has the potential to improve reporting of eczema control in
research and clinical practice. Further exploration of measurement properties is
required.
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What’s already known about this topic?
• Eczema control has been identified as an important outcome by key stakeholders
in eczema research (including patients, carers, healthcare professionals and
researchers).
• Qualitative studies suggest eczema control is a multifaceted and individual experi-
ence and no instrument has been identified that captures eczema control in this
way.
What does this study add?
• We have developed Recap of atopic eczema (RECAP), a seven-item questionnaire
to capture the experience of eczema control in all ages and eczema severities; there
are two versions: a self-reported version for adults and older children with eczema,
and a caregiver-reported version for younger children with eczema.
• Designed with input from people with eczema, caregivers and healthcare profes-
sionals to ensure good content validity.
• Initial testing of score distributions and construct validity suggests good measure-
ment properties.
What are the clinical implications of the work?
• The RECAP instrument is appropriate and feasible for measuring eczema control in
clinical trials and may also be useful in routine practice.
Atopic eczema (syn. eczema, atopic dermatitis) is a common,
chronic condition that is characterized by itchy, dry skin that
can become cracked and sore and often has a relapsing and
remitting disease course. The Harmonising Outcome Measures
in Eczema (HOME) initiative recommends ‘long-term control
of eczema’ as a core outcome domain that should be mea-
sured in every clinical trial over 3 months’ duration, indicat-
ing that it is an important outcome for a range of stakeholders
(including patients, carers, healthcare professionals and
researchers).1 Consensus voting at the HOME V meeting in
June 2017 identified the need for a patient global assessment
of eczema control.2
Qualitative research involving people with eczema, their
caregivers and healthcare professionals suggests that eczema
control is a multifaceted construct involving changes in disease
activity, the treatment and management of the condition and
psychological, social and physical functioning.3,4 Measuring
such a complex construct over time can be challenging, but
instruments to capture long-term control have been developed
in other chronic diseases such as asthma and urticaria.5,6
This study aimed to develop a new outcome measurement
instrument to capture a patient’s perspective of eczema control
for use in research and clinical practice. The study objectives
were to: (i) develop an instrument to capture eczema control
that is suitable for use in both adults and children with
eczema and (ii) conduct preliminary validation of the new




This mixed-methods study included five stages of instrument
development as summarized in Figure 1. Methodological
guidance for instrument development was followed.7–11 The
development process was guided by an international expert
panel consisting of three dermatologists, a dermatology nurse,
a general practitioner, two adults with eczema, two caregivers
of children with eczema, four methodologists and a psycholo-
gist. Five countries (UK, Germany, Sweden, the Netherlands
and Australia) were represented on the expert panel. This pro-
ject has been approved by the University of Nottingham’s Fac-
ulty of Medicine & Health Sciences Research Ethics Committee
(Refs: 18-1805 and F14062016 SoM ROD). Both the protocol
and data analysis plan were uploaded to the registration portal
of the Centre of Evidence Based Dermatology (CEBD) a priori
and can be referred to for further methodological details of
the study (https://www.nottingham.ac.uk/research/groups/
cebd/resources/protocol-registration.aspx).
Stages of instrument development
Stage 1: develop and refine the conceptual framework
Table 1 outlines the intended purpose of the instrument.
The qualitative studies and HOME V meeting discussions
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suggest that the focus of this instrument should be individ-
ual ‘perceptions’ of eczema control. It also is worth noting
that this construct as defined is not related to perceptions
about the ‘controllability of eczema’, which might relate to
what an individual thinks they can do, or what their treat-
ment can do, to control their eczema, but about the attain-
ment of control perceived when reflecting on their
experience. The details of what are ‘indicators of control’
are presented in the conceptual framework (Fig. 2). The
conceptual framework was drafted by L.M.H., J.R.C., C.A.
and K.S.T. through synthesizing findings from an interna-
tional qualitative study,3,4 an international patient survey12
and a systematic literature review13 relating to the construct
of interest.
A 2-h face-to-face focus group involving people with
eczema and caregivers of children with eczema was conducted
to confirm the conceptual framework and to ensure that key
items had not been overlooked. This focus group was
moderated by C.A., who has experience in moderating groups
and training in qualitative research. The focus group followed
a topic guide that included open discussion about the
construct of interest, followed by discussion focused on the
conceptual framework (Appendix S1; see Supporting informa-
tion). The focus group was recorded and transcribed verbatim.
The findings from the focus group were discussed by the
expert panel who used this conceptual framework as a starting
point to begin item design. The conceptual framework devel-
oped suggests this instrument requires a formative measure-
ment model, which has impacted the methodology choices
later in the development process.
Stage 2: item generation
Driven by the conceptual framework and a short guidance
document on constructing questions the expert panel mem-
bers submitted ideas for items to include in the
Fig 1. Study design for developing Recap of atopic eczema (RECAP).
© 2019 The Authors. British Journal of Dermatology
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instrument.9,14 The items were then categorized and discussed
by the panel. The items were either discarded, kept or
amended to produce an initial working list of items.
Stage 3: item refinement
Cognitive interviews, which used a range of think-aloud and
probing techniques, were used with the aim to improve the
comprehension, comprehensibility and relevance of the ques-
tionnaire. The target population was adults (16+ years) with
eczema or caregivers of children with eczema living in the
UK. Children under 16 years of age could take part if their
caregiver was present. Participants were recruited using exist-
ing mailing lists held at the CEBD in Nottingham of people
interested in eczema-related research and through social
media. All participants had to be proficient in English. There
was no exclusion of participants based on age, eczema sever-
ity, sex or ethnicity and purposeful sampling aimed to achieve
a diverse range of participants based on these characteristics.
Cognitive interviews lasting approximately 1 h each took
place either face to face, on the telephone, or via video call
depending on participant preference. All interviews were con-
ducted by L.M.H., who has experience and training in qualita-
tive research and the team received further support from a
methodological advisor (Dr Paul Leighton, P.L.). Interviews
followed a semi-structured interview guide (Appendix S2; see
Supporting information). The participants were asked to
answer the items using think-aloud methods.15 The inter-
viewer planned breaks to summarize and use pre-planned
probes to encourage elaboration by participants. Once the




The experience of eczema control. This was
defined in this study as ‘the extent to which
the various manifestations of eczema and the
impact that these have for an individual are
removed or meaningfully reduced’
Intended target
population
Individuals with eczema of all ages. However,
for younger children who do not have the
cognitive abilities to answer the
questionnaire alone, it is intended that the
information will be provided by caregivers
or with the assistance of caregivers. The
questionnaire is not intended to be exclusive
to use in a single disease severity, disease
duration, sex or ethnicity
Intended context
for use
Primarily designed for use in clinical trials
assessing any type of intervention in people
with eczema. As a secondary aim, it was also
anticipated that the instrument should be
appropriate for use in clinical settings
Fig 2. Initial conceptual framework discussed at focus group.
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2020)
4 Development and initial testing of RECAP, Howells et al.
think-aloud process was applied to all items, the interviewer
then probed the participants about the items as a global set.
Interviews took place in rounds, with the expert panel refining
the content in between rounds, and subsequent rounds assess-
ing if the changes had addressed the initial problems. It was
planned that rounds would be continued until no further
refinements were required. All interviews were recorded and
transcribed verbatim.
Stage 4: item selection
An online survey was used to conduct an impact analysis,
which uses information about frequency of occurrence and
the importance of the experiences to assess the relevance of
each item. The aim of impact analysis is to assess the impor-
tance of each item, as formative models require that the most
important items are represented. The survey was also used to
conduct a backward stepwise regression analysis. The aim of
regression analysis is to reduce the number of items and
ensure that each item adds unique information about the
experience of eczema control. The target population was the
same as for Stage 3, as were the recruitment methods,
although the latter was supplemented with the use of posters
in various public settings (shops, cafes, libraries, universities,
healthcare centres).
Variables included in the survey were age, sex, ethnicity,
‘bother caused by the eczema’, global eczema severity, the
Patient-Oriented Eczema Measure (POEM), and items being
considered for inclusion following the item refinement stage.
Participants also indicated if that experience had occurred for
them/their child over the past year and how important this
experience is when thinking about their/their child’s eczema.
Stage 5: instrument scoring and preliminary validation
The online survey described in Stage 4 was also used to collect
data on the final items chosen for inclusion so that these could
be scored and tested. Overall scores for the final items were
generated using scoring rules determined by the expert panel.
These scores were then tested for distribution of scores. The
aim was to ensure that the items did not produce a score with
a floor or ceiling effect, which is where a high proportion of
the total population has a score at the lower or upper end of
the scale, respectively.7 They were also tested for construct
validity, which aims to assess the degree to which the scores
of the instrument are consistent with hypotheses that are
based on the assumption that the instrument validly measures
the construct to be measured.16
Analysis
Focus group for Stage 1: develop and refine the
conceptual model
Experiences of eczema control were mapped onto the theoreti-
cal framework used in previous concept elicitation studies.3,4
L.M.H. and P.L. independently coded the data and met to dis-
cuss any discrepancies in coding. A qualitative descriptive
approach was used to analyse the participants’ responses to
the conceptual framework.17
Cognitive interviews for Stage 3: item refinement
Data were analysed using a top-down coding approach, and
refined with inductive coding (Table S1; see Supporting infor-
mation). All data were analysed by L.M.H., with secondary
coding on selected transcripts by J.R.C. or A.V.S. As it was
not possible with the resources available for all transcripts to
be coded, transcripts for secondary coding were selected to
include both early and final interviews, interviews containing
a variety of problems across the coding framework, and
selected transcripts with difficult-to-code problems. Discrepan-
cies in coding were discussed and resolved via discussion.
S.G., K.S.T., L.M.H. and J.R.C. were all involved in ongoing
discussions about the coding and between each round of
interviews; any problems that were identified and potential
solutions were fed back to the expert panel for their input.
Based on a saturation model, interview rounds continued to
test if problems from previous interview rounds were
resolved until the authors were satisfied that there were no
major problems that could be resolved via further cognitive
interviewing. The final round tested items in the final word-
ing that was then used in the online survey for further item
reduction.
Online survey for Stages 4 and 5: item selection,
instrument scoring and preliminary validation
Data were analysed using Stata 15.
Impact analysis. For each item concept, the proportion of indi-
viduals who had experienced that in the past year was multi-
plied by the mean score of the importance rating (1, not
important; 5, extremely important) to give an impact score
ranging from 0 to 5. Whole-sample analysis and subgroup
analysis by age of person with eczema (0–4 years, 5–15 years,
16+ years) were decided a priori. It was predefined that an
impact score of less than 2 in any group analysed indicated
that an item should not be considered for inclusion in the
instrument, as was used in the development of the Urticaria
Control Test.5
Multivariable regression analysis. The potential items were entered
as independent variables into multivariable linear regression
models. The dependent variable was ‘bother caused by
eczema’ (0–10 points). This dependent variable was chosen
because there was no ‘gold standard’ measure of ‘eczema con-
trol’ that could be used. ‘Bother caused by the eczema’ was
agreed by the expert panel to be the most closely aligned
measure available (it has been used in previous eczema
research) with the concept of ‘eczema control’ as defined for
the development of Recap of atopic eczema (RECAP). Sample
size was calculated as at least 10 cases per independent vari-
able. The backward elimination variable selection technique
© 2019 The Authors. British Journal of Dermatology
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was used to determine which items remained in the model.
The stopping criteria for this process was P = 0157, which is
recommended for sample sizes with between 10 and 25
events per parameter.18 The assumptions of multicollinearity,
linearity, normality of residuals and homoscedasticity of resid-
uals were met.
Scoring. The expert panel agreed scoring rules resulted in all
RECAP items being scored from 0 to 4 and weighted equally
and added together (total scores ranging from 0 to 28), with
a higher score indicating less eczema control.
Distribution of scores. Assessment of histograms. A floor or ceil-
ing effect was defined prior to data collection as more than
15% of participants achieving the highest or lowest possible
score.19
Construct validity. Convergent validity assesses if instruments
that are theoretically measuring similar constructs are related.
POEM measures the construct of ‘eczema-related morbidity’
by monitoring eczema symptoms over the last week. A sys-
tematic review that included studies looking at the measure-
ment properties of POEM concluded that there was limited
evidence for good internal consistency, moderate evidence for
good construct validity, good responsiveness and good content
validity, and unclear evidence of test–retest reliability and
measurement error.20–23 Interpretation of POEM has been
assessed in the form of the minimally important change and
severity bandings.21,24–26 Pearson’s correlation coefficients
were used to assess the relationship between POEM (measur-
ing patient-reported symptoms) and the newly developed
instrument. It was hypothesized that correlations would be at
least 03 (moderately correlated). Discriminative validity is
where a measurement instrument is able to distinguish
between subgroups of patients. This can be done by compar-
ing the mean scores on the measurement instrument for the
subgroups.7 Subgroups of participants were categorized based
on scores from a global eczema severity measure and POEM
severity categories.25 It was hypothesized that there would be
a linear trend of higher mean RECAP scores for each subgroup
of participants categorized with more severe eczema on the
global eczema severity measure and the POEM severity cate-
gories.
Patient and public involvement
As expert panel members, two patients and two caregivers
took part in face-to-face/video meetings, teleconferences
and email feedback to co-design items and input into deci-
sions throughout the process. All reviewed the wording and
design of materials (including information sheets, consent
forms, advertisement/posters, the online survey). N.K.R. and
T.B. piloted the cognitive interview process to give the
interviewer feedback on the process. The CEBD Patient
Panel day (a patient and public involvement day at the
University of Nottingham) provided input during the item
refinement process with some key, targeted queries to aid




Details of the number of participants, sex and self-reported
ethnicity (where available) are reported for the focus group
(Stage 1) and the cognitive interviews (Stage 3) in Table 2.
Self-reported eczema severity ranged from mild to very severe
in both the focus group and the cognitive interviews. For the
interviews, the age of adults with eczema ranged from 37 to
64 years and all reported onset of eczema as young children.
The age of the children of the caregivers taking part ranged
from 2 years and 8 months to 14 years. Onset of eczema was
reported from 8 weeks old to 2 years and 6 months old. A
total of 330 took part in the online survey (Stages 4 and 5),
but six of these participants completed only demographic vari-
ables. Table 3 provides the participant characteristics for the
online survey.
Key stages of instrument development
Stage 1: develop and refine the conceptual framework
Figure 2 shows the initial conceptual framework that was
presented to members of the focus group (although more
detail was included relating to each concept). Mapping to
the thematic framework indicated that data saturation for
concept elicitation was reached. Participants confirmed that
the framework represented an accurate model of ‘eczema
























aEthnicity stated have been preserved as the participants reported.
bAlthough only one person took part primarily as a caregiver,
there were an additional two participants who are classified as
adults with eczema in this table, but they also had experiences
of caring for their children with eczema.
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control’ and that the conceptual framework was comprehen-
sive. Nevertheless, some minor refinements were suggested,
as summarized in Table 4. The final conceptual framework
for the RECAP instrument, after refinement based on all
stages of instrument design is presented in Figure 3. The
conceptual framework suggests that a formative model is the
best approach to developing the measurement model for this
construct of interest as multiple unique factors are relevant to
the experience, which, when combined together, form the
latent variable.7
Stage 2: item generation
Fourteen expert panel members were each asked to submit
questions that could be used to capture the key elements
of eczema control as outlined in the conceptual framework.
This process resulted in an initial list of 154 ideas,
although many of the ideas gave multiple alternate options
to capture the same concept. Using these as a starting
point, the expert panel worked together to group, discard
and amend items and make key decisions on how to pre-
sent the items (e.g. number of response options). On the
basis of this discussion, the lead researcher compiled a list
of 25 items that were then revised and approved by the
expert panel to be tested in the next phase of the develop-
ment process.
Stage 3: item refinement
Thirteen interviews took place over four rounds (round 1, n
= 5; round 2, n = 3; round 3, n = 4; and round 4, n =
1). The changes that took place over four rounds of cogni-
tive interviews were: the recall period was changed from 4
weeks to 1 week; the number of response options was
increased from four to five; the items were changed from
statements to questions; the wording was changed to pro-
vide clarity; and the language was amended to reflect terms
respondents felt had greater resonance and that increased
the confidence of respondents in their ability to answer the
questions (Table S2; see Supporting information). By the
end of the interviews 15 items remained for further testing.
Detailed results of this analysis are presented in
Appendix S3 (see Supporting information). However, only
14 items were included in subsequent analysis as the expert
panel made the decision to remove the remaining treat-
ment-related item, having reflected on the HOME V meeting
decisions about the feasibility of treatment-related measures,
the cognitive interview findings and the conceptual frame-
work refinements.
Stage 4: item selection
Impact analysis. Data on frequency, importance and impact
scores from the online survey are presented in Table 5. ‘Feel-
ing self-conscious’ scored less than 2 in the age group 0–4
years and ‘feeling isolated’ scored less than 2 across all ages,
in the age group 0–4 years and the age group 16+ years. It
was predefined that any item with an impact score of < 2 for
any of our target groups was considered not relevant and
therefore these two items were excluded from the subsequent
regression analysis. Items on the ‘acceptability’, ‘overall indi-
vidual perception’ and ‘treatment been enough’ were not
included in the impact analysis due to the expert panel
appraising that it was not appropriate to assess the frequency
and importance of these items.
Multivariable linear regression analysis. Two models were devel-
oped. The first model contained all 12 items that were still
under consideration for inclusion in the final set of items as
predictor variables. ‘Bother caused by the eczema’ was used as
the outcome variable. Five predictor variables were removed
from the model following a backward elimination item reduc-
tion technique with a stopping criterion of P = 0157. These
Table 3 Online survey participant characteristics
n % Mean ( SD) Range
Age (years) 324 – 2271 0–66
Under 5a 62 191 – –
5–15a 77 238 – –
16+ 185 571 – –
Sex 324 – – –
Male 110 3395 – –
Female 211 6512 – –
Nonbinary 2 062 – –
Rather not say 1 031 – –
Ethnicity 322 – – –
White 300 9317 – –
Bangladeshi 1 031 – –
Black Caribbean 2 062 – –
Chinese 6 186 – –
Indian 6 186 – –
Mixed race 5 155 – –
Other Asian
(non-Chinese)
1 031 – –
Sikh 1 031 – –
Total POEM score 263 – 1512  737 0–28
POEM severity banding 263 – – –
Clear/almost clear 13 49 – –
Mild 33 125 – –
Moderate 95 361 – –
Severe 96 365 – –
Very severe 26 99 – –
Global severity 266 – – –
Clear 6 23 – –
Almost clear 34 128 – –
Mild 65 244 – –
Moderate 121 455 – –
Severe 40 150 – –
Bother caused by
the eczemab
324 – 565  256 0–10
aFor under 16-year-olds the survey was completed by a caregiver
in 95% of cases (n = 132). bHow much bother has your/your
child’s eczema been over the past week? Responses from 0 (no
bother at all) to 10 (as much bother as you can imagine) POEM,
Patient-Oriented Eczema Measure.
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included items ‘being unable to stop scratching’ (P = 0809),
‘stopped from doing something wanted or needed to do’
(P = 0438), ‘having flares’ (P = 0314), ‘having any symp-
toms’ (P = 0809) and ‘painful or sore skin’ (P = 0612). The
results of the regression indicated that the seven remaining
predictor variables explained 711% of the variance in ‘bother
caused by the eczema’, R2 = 0718, adjusted R2 = 0711, F(7,
256) = 9319, P < 0001. Table 6 shows the predictor vari-
ables that remained in the model.
The second model contained 10 items as it excluded ‘accept-
ability’ and ‘overall individual perception’ due to expert panel
concerns that the more global nature of these items may remove
important but more specific items. Appendix S4 and Table S3
(see Supporting information) show the full results of Model 2.
The expert panel agreed Model 1 as the final set of items using
the evidence from all previous stages of development. Model 1
was considered to be comprehensive and explained a larger pro-
portion of the variance than Model 2 (Model 2: R2 = 0627,
adjusted R2 = 0615, F(8, 256) = 5374, P < 0001). The final
RECAP instrument can be found in Figure 4.





Participants at the focus group expressed a concern that the predictability of eczema, which related to eczema
control in their perception, was not included in the conceptual framework.
Removal of item on
predictability
The cognitive interviews suggested that an item asking directly about the predictability of the eczema was
not interpreted in line with the construct of interest. It may be that this concept is a related but distinct
outcome to be measured.
Removal of concept impact
on family
The expert panel meeting led to discussions about designing items on the impact on family and it was felt
strongly among stakeholders including patients that this concept was not universal to all. It was also
suggested to be a related but distinct construct.
Removal of treatment and
management concepts
The cognitive interviews revealed issues regarding the applicability and relevance of treatment items. The
expert panel discussed these findings and reviewed the inclusion of these concepts within the framework.
Some members wanted these concepts to remain, while others felt they were not part of the construct of
interest. The discussions at the HOME V consensus meeting were also referred to, which indicated that
stakeholders did not think treatment-related items were feasible in all clinical trials. Issues that were
considered when making this decision:
1 Treatment- and management-related questions are answered differently depending on disease severity and
type of treatment used. For example, only people with more severe eczema will have access to systemic
therapies.
2 There is difficulty in distinguishing between answers that relate to eczema control and answers that relate
to personal choice (e.g. a patient who does not want to use a particular treatment but has low level of
control may answer in a way that appears congruent with good control).
3 In many clinical trial situations it is not always possible for patients to change or step up/step down their
treatment so these concepts are not always applicable, but were one of the main features of understanding
level of control in a nontrial setting by stakeholders who inputted into the conceptual model.
The online survey revealed that the items regarding social impacts were not applicable and relevant to
young children. This finding was discussed among the expert panel who approved removing this concept.




In the initial conceptual model, ‘an acceptable level of control is an individual experience’ was an
overarching concept that was considered important, but it was not initially clear how this fit within the
design of the instrument. Through expert panel discussions when interpreting the findings from the face-to-
face focus group and designing items, it was acknowledged that items about the ‘acceptability of eczema’ to
an individual and the individual’s personal overall perception of ‘how the eczema had been’ were unique
perceptions about the experience of eczema control that could be included as items in the measure.
HOME, Harmonising Outcome Measures for Eczema.
Fig 3. Final conceptual framework. Note. The direction of the arrows
indicates that a formative measurement model is most appropriate to use.
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Stage 5: instrument scoring and preliminary validation
Each of the seven questions in RECAP carries equal weight and
is scored from 0 to 4 (total score of 0–28). The full scoring
details are shown in Appendix S5 (see Supporting information).
Figure 5 shows a normal distribution of scores and no floor or
ceiling effects are present. The scores for the final instrument
were significantly positively correlated with POEM scores,
r(258) = 083, P < 0001, which is in line with the hypothesis
about convergence validity (construct validity). Table 7 illus-
trates how each increase in severity banding according to estab-
lished POEM severity bandings and a single item global severity
measure corresponded with a larger mean RECAP score for those
scoring within that severity category,25 which is in line with
hypotheses about discriminative validity (construct validity).
Discussion
RECAP is a patient- or caregiver-reported instrument to cap-
ture ‘an individual’s experience of eczema control’ intended
for use in clinical trials and routine care. RECAP, comprising
just seven questions, represents a practical and feasible
approach to capturing a patient/caregiver’s perspective of
eczema control. The development process was designed to
maximize the comprehensiveness, comprehensibility and rele-
vance of the items to patients and caregivers while producing
a tool that was feasible.16
How eczema control is conceptualized has implications for
the most appropriate measurement model to use in developing
RECAP. The study team engaged in multiple discussions about
whether the construct of interest for RECAP was best consid-
ered as a reflective or a formative model. It was considered
that each item was tapping into a different characteristic and
contributing part of the construct, and when considered
together they form the whole construct. Therefore, it was
decided that a formative model was most appropriate. Further-
more, eczema control is a complex construct and therefore it
was considered difficult to capture using only a single ques-
tion, particularly as the term ‘control’ has multiple meanings
in everyday language and can be interpreted in different
ways.27
Given that eczema control includes a dimension of time, it
was considered important to ask about experiences of eczema
during a defined period rather than ‘at the moment’. It was
initially felt that a 4-week recall period may be a better indica-
tor of ‘long-term’ control. However, the 4-week period used
at the start of the study was found to affect the ability of
patients to calculate a response due to difficulties with recall
and if their eczema had varied greatly over that period of time,
averaging out their experience.28 The chosen recall period of
‘the last week’ is in line with US Food and Drug
Table 5 Results of impact analysisa
Age group (years)
Frequency (proportion) Importance (mean score)
Impact score (frequency 9
importance)
All 0–4 5–15 16+ All 0–4 5–15 16+ All 0–4 5–15 16+
Itchy skin 1 1 1 1 477 489 482 47 477 489 482 470
Flare 09963 1 1 09935 46 481 464 45 458 481 464 447
Had any symptoms 09963 1 1 09935 457 463 454 455 455 463 454 452
Skin painful or sore 09925 1 0965 1 463 474 473 456 460 474 456 456
Intensely itchy skin 09736 09811 09649 09742 455 474 466 445 443 465 450 434
Unable to stop scratching 09586 09444 09474 09677 458 47 479 446 439 444 454 432
Eczema affecting how been feeling 0937 09259 09298 0941 44 45 459 429 412 417 427 404
Disturbed sleep 09023 09259 09483 08766 424 435 481 399 383 403 456 350
Eczema getting in the way of
day-to-day activities
08647 08148 08966 08701 421 422 447 412 364 344 401 358
Stopped from doing something
wanted or needed to do
07895 07222 08621 07806 414 417 438 404 327 301 378 315
Feeling self-conscious or embarrassed 07857 02778 08596 09355 43 361 459 439 338 100b 395 411
Feeling isolated 04906 01852 0569 05677 35 354 428 315 172b 066b 244 179b
aItems on the ‘acceptability, ‘overall individual perception’, and ‘treatment been enough’ were not considered appropriate for inclusion in
the impact analysis. bAn impact score of < 2 was defined a priori as indicating an experience was not relevant to include in the multivariable
linear regression analysis.
Table 6 Model 1 Final output (all items included in the final RECAP
instrument), n = 264
Predictor variables b P-value 95% CI
Acceptability of eczema 030 0017 005–055
Itchy skin 019 0053 –0002 to 038
Sleep disturbance 014 0127 –004 to 032
Getting in the way of
day-to-day activities
032 001 008–055
Affecting how been feeling 013 0102 –003 to 029
Intensely itchy skin 022 0009 006–039
Global 092 > 0001 071–124
CI, confidence interval; RECAP, Recap of atopic eczema.
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(a)
Fig 4. Recap of atopic eczema (RECAP) questionnaire (copyright retained by authors): (a) self-reported version and (b) caregiver-reported
version.
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(b)
Fig 4. Continued
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Administration guidance, which states a preference for items
that ask patients to describe their current or recent state.8
Regarding strengths and limitations, this instrument was
purposefully developed so that it could be applied across all
age groups and a self-report and caregiver-report version have
been developed simultaneously to create a measure that will
work across all trial populations. This quick-to-complete instru-
ment could be transferred easily to online or smartphone appli-
cation platforms. The questionnaire is free to access and use.
It may be that there are some differences in the ways that
individuals who have eczema and caregivers perceive eczema
control, which further research should explore. The initial
development phase involved testing of the instrument in a UK
population and in the English language only due to resources
available. However, involvement of stakeholders across differ-
ent countries in the development team was utilized to try and
anticipate any difficulties in adaptation and translation that
could be foreseen by the team. The recruitment methods were
varied to try and reach different audiences. However, it is pos-
sible that there are potential biases in the types of people who
would be willing to take part in focus groups, interviews and
online surveys voluntarily.
In conclusion, RECAP is a new instrument to capture
‘eczema control’ over the past week. It was developed accord-
ing to best practice for the development of patient-reported
outcome measures. Further studies are now required to con-
firm the psychometric properties of the RECAP instrument in
different populations and to confirm the suitability of RECAP
for use in research studies and clinical practice.
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